Your browser is no longer supported

For the best possible experience using our website we recommend you upgrade to a newer version or another browser.

Your browser appears to have cookies disabled. For the best experience of this website, please enable cookies in your browser

We'll assume we have your consent to use cookies, for example so you won't need to log in each time you visit our site.
Learn more

New prostate drug approved by EU regulators

  • Comment

Regulators have passed GlaxoSmithKline’s prostate drug Duodart for use in the EU, the company has announced.

The two-in-one treatment, used to alleviate the symptoms of an enlarged prostate, contains dutasteride, currently marketed as Avodart, and tamsulosin, sold as Flomax.

Approval was granted in Germany under the EU’s decentralised approval procedure, meaning it is applicable across the 27-member bloc. Individual national licences are expected to follow.

Prostate enlargement is an increasingly common problem for men as they age. Almost four in 10 over-65s have the condition, which occurs when there is an overgrowth of cells in the prostate gland, blocking the flow of urine.

It is thought that Glaxo eventually plans to use Avodart as a prostate cancer treatment after earlier research showed the drug reduced the risk of contracting the condition by around 25%.

  • Comment

Have your say

You must sign in to make a comment

Please remember that the submission of any material is governed by our Terms and Conditions and by submitting material you confirm your agreement to these Terms and Conditions. Links may be included in your comments but HTML is not permitted.

Related Jobs